『SoCCC Pre-Rounds: Bite-Sized Critical Care Cardiology Topics Delivered By Experts』のカバーアート

SoCCC Pre-Rounds: Bite-Sized Critical Care Cardiology Topics Delivered By Experts

SoCCC Pre-Rounds: Bite-Sized Critical Care Cardiology Topics Delivered By Experts

著者： Dr. Balim Senman Dr. Elliott Miller Dr. Simon Parlow Dr. Anthony Carnicelli
無料で聴く

SoCCC Pre-Rounds is your go-to for quick, high-yield insights in critical care cardiology, hosted by members of the Society of Critical Care Cardiology (SoCCC). With only 160 specialists in the U.S., mentorship is rare. This podcast bridges the gap with bite-sized episodes featuring clinical pearls, expert tips, and real-world answers on topics like cardiogenic shock, ECMO, and resuscitation. Perfect for pre-rounds, night shifts, or leveling up anytime. Listen in. Level up. Join the SoCCC community.Dr. Balim Senman, Dr. Elliott Miller, Dr. Simon Parlow, Dr. Anthony Carnicelli 衛生・健康的な生活 身体的病い・疾患
エピソード
  • Vasoactive Medications in the CICU with Dr. Elliott Miller and Dr. Anthony Carnicelli

    Vasoactive Medications in the CICU with Dr. Elliott Miller and Dr. Anthony Carnicelli
    2026/07/03
    How do you choose the right vasoactive medication for a patient in cardiogenic shock? In this episode of SoCCC Pre-Rounds, hosts Dr. Anthony Carnicelli and Dr. Elliott Miller sit down for a practical, high-yield discussion on vasopressors, inotropes, and the real-world decision-making behind vasoactive medication management in the CICU.Designed for residents, fellows, and ICU teams, this episode breaks down the pharmacology, clinical evidence, and bedside application of commonly used vasoactive agents including norepinephrine, dopamine, epinephrine, vasopressin, phenylephrine, dobutamine, and milrinone.Dr. Carnicelli emphasizes a stepwise approach to vasoactive medication management: first understanding the pharmacology and intended physiologic effects, then learning how to apply those principles clinically in complex shock states. The conversation explores the limitations of existing cardiogenic shock data, including the aging SOAP II trial and the landmark DOREMI trial comparing milrinone and dobutamine.The discussion also dives into nuanced scenarios such as LVOT obstruction, severe aortic stenosis, pulmonary hypertension, arrhythmogenic shock, and escalating vasopressor requirements that may signal the need for mechanical circulatory support.Packed with practical teaching pearls and candid reflections from the CICU, this episode offers a thoughtful framework for approaching vasoactive medications beyond algorithms and dogma. Whether you are pre-rounding before sunrise or managing a crashing patient overnight, this episode delivers actionable insights you can apply immediately at the bedside.Norepinephrine remains the preferred first-line vasopressor in most cardiogenic shock patients.Vasopressin is generally avoided in low-output cardiogenic shock due to pure vasoconstrictive effects.Pulmonary hypertension and arrhythmogenic shock may be scenarios where vasopressin is helpful.DOREMI demonstrated no major efficacy or safety differences between milrinone and dobutamine.Vasoactive medication management is often more art than science.[00:00] Introduction [01:51] A two-step approach to teaching vasoactive meds[03:30] The SOAP II trial: Norepinephrine vs. dopamine[06:41] Epinephrine as a first-line agent[08:19] When to avoid norepinephrine[09:57] Using vasopressin in cardiogenic shock[12:32] Phenylephrine in right heart failure[13:48] The DOREMI trial: Milrinone vs. dobutamine[17:32] Final thoughts and interdisciplinary approaches[07:37] " Even if you're defending the MAP with epinephrine, you'll get this characteristic rise in lactate, which is concerning, to say the least." — Dr. Elliott Miller[15:36] "The fact that in a randomized trial there was no evidence of efficacy difference, no difference in survival, but also no difference in safety profile…that speaks volumes." — Dr. Anthony Carnicelli on the DOREMI trial[17:07] "If you choose milrinone and you've made a mistake, you're going to have to live with that mistake for a lot longer than dobutamine." — Dr. Elliott Miller[18:51] "Vasoactive medication management is a bit more of an art than it is a science. So experience goes a long way." — Dr. Anthony CarnicelliResources and LinksBecome a member of the Community: https://www.soccc.org/subscribeDr. Anthony Carnicellihttps://www.getcare.muschealth.org/providers/anthony-carnicelli-1376956714https://www.linkedin.com/in/anthony-carnicelli-926a0b88Dr. Elliott Millerhttps://x.com/ElliottMillerMDhttps://www.soccc.org/Supported By:This episode is made possible by unrestricted support from Zoll LifeVest — thanks for keeping high-impact education free for our community.DisclaimerThis podcast is not medical advice, just candid, practical discussions about what your hosts do every day in the CICU. Always consult your supervising team and current guidelines before applying any interventions.
    続きを読む 一部表示
    20 分
  • The Story of DanGer Shock and the Future of the Microaxial Flow Pump with Dr. Jacob Møller

    The Story of DanGer Shock and the Future of the Microaxial Flow Pump with Dr. Jacob Møller
    2026/06/05
    After more than two decades without a major positive randomized trial in cardiogenic shock, is the evidence finally catching up to the technology? In this episode of SoCCC Pre-Rounds, Dr. Simon Parlow sits down with Dr. Jacob Møller, critical care cardiologist and professor at the University Hospital Copenhagen, to unpack microaxial flow pumps and the landmark DanGer Shock trial. Dr. Møller shares how persistence, collaboration, and a bit of luck helped drive a breakthrough in a field that has long needed one.They explore how these devices work at the bedside, from unloading the left ventricle to reducing myocardial oxygen demand, and what that means in real-world care. The conversation also dives into the challenges of running a high-stakes trial in critically ill patients, along with practical insights on patient selection, complications, lactate trends, and weaning strategies. It’s a sharp look at one of the most important recent advances in cardiogenic shock and where clinicians are still forced to operate without clear evidence.Microaxial flow pumps unload the left ventricle: By reducing preload and stroke work, they may lower myocardial oxygen demand and support recovery in shock states.The DanGer Shock trial changes the landscape: It’s the first major positive randomized trial in cardiogenic shock in over 20 years, targeting a highly selected STEMI population.Patient selection is everything: Only a small fraction of shock patients were eligible, highlighting how precise clinicians must be when applying this therapy.Weaning starts earlier than we thought: The most critical window may be the first 12–24 hours, with earlier reassessment for device removal.Evidence is still evolving: Outside of trial populations, clinicians must rely on judgment when considering use in non-STEMI or non-ischemic shock.[00:00] Introduction to SoCCC Pre-Rounds[00:57] Live from ACVC 2026: introducing Dr. Jacob Møller[01:15] What are micro axial flow pumps and how do they work?[03:52] The origin and evolution of the DanGer Shock trial[06:39] Trial results and why they were unexpected[07:48] Expanding beyond STEMI: real-world patient selection[09:44] Monitoring patients: lactate and hemodynamic trends[10:20] Early management challenges and complications[11:36] Rethinking weaning strategies[12:05] Role of guideline-directed therapy during support[12:57] Lessons from running a major clinical trial[14:03] Building a research culture in critical care[07:51] "After seeing the results of DanGer, we have probably become a little bit more liberal in using the device in other forms of ischemic, like non-STEMI shock." — Dr. Jacob Møller[09:46] "We look at trajectories, and we look a lot at lactate. Lactate has to go down in these patients; otherwise, something is wrong." — Dr. Jacob Møller[10:33] "You look at the trajectory, so if it goes from 1.5 and starts going down, then you know there's something wrong." — Dr. Jacob Møller[13:57] "I'm working in a very small cardiac ICU; we only have seven beds, but we randomized more than 100 patients with out-of-hospital cardiac arrest every year." — Dr. Jacob MøllerBecome a member of the Community: https://www.soccc.org/subscribeDr. Jacob Møllerhttps://www.linkedin.com/in/jacob-eifer-m%C3%B8ller-1b2398300/?locale=enhttps://www.rigshospitalet.dk/Dr. Simon Parlowhttps://www.ottawaheart.ca/profile/parlow-simonSupported By:This episode is made possible by unrestricted support from Zoll LifeVest — thanks for keeping high-impact education free for our community.DisclaimerThis podcast is not medical advice, just candid, practical discussions about what your hosts do every day in the CICU. Always consult your supervising team and current guidelines before applying any interventions.
    続きを読む 一部表示
    15 分
  • Keeping It Cool: The Evidence, the Controversy, the Future of TTM with Dr. Andrea Elliott

    Keeping It Cool: The Evidence, the Controversy, the Future of TTM with Dr. Andrea Elliott
    2026/05/01
    In this episode of SoCCC Pre-Rounds, Dr. Balim Senman and Dr. Andrea Elliott, a cardiologist and critical care physician at the University of Minnesota, dive into the evolving landscape of targeted temperature management (TTM) after cardiac arrest. They explore how temperature control strategies have shifted from early hypothermia trials to modern fever-avoidance methods, with ongoing debates around TTM in critical care. Dr. Elliott discusses landmark studies like Bernard, HACA, TTM, Hyperion, and TTM2, highlighting their impact and limitations.The conversation delves into the real-world application of temperature targets, considering patient severity, neurologic injury, and the unique challenges posed by ECPR patients. Dr. Elliott also covers the physiological costs of hypothermia, common complications, and practical aspects of managing shivering, devices, and protocols. Whether you're a trainee or an experienced clinician, this episode offers evidence-based insights and practical guidance for optimizing post-arrest care.TTM is for comatose survivors: Only patients who remain unresponsive after ROSC benefit; awake patients do not.Fever prevention matters most: Trial data on hypothermia vs normothermia are mixed, but fever (>37.7°C) is consistently harmful and must be aggressively avoided.One size does not fit all: Patients with longer downtimes or more severe neurologic injury may benefit more from active cooling. Allowing spontaneous hypothermia is reasonable.ECPR patients are different: Prolonged CPR and ECMO-based temperature control make them physiologically distinct from patients in major TTM trials.In This Episode[00:00] Introduction[02:16] Historical background of TTM[03:13] Early human studies and mechanisms[04:17] Landmark trials Bernard and HACA[06:06] TM1 Hyperion and TM2 trials[10:25] Patient selection for TTM[11:39] Personalized temperature targeting[13:21] Management of hypothermic and normothermic patients[15:47] TTM in ECPR and ECMO patients[18:09] Drawbacks and risks of hypothermia[19:19] Protocols and cooling devices[21:59] ECPR-specific cooling techniquesNotable Quotes[16:04] "ECPR patients by definition have had refractory arrest, not attaining ROSC. So that 20- 25 minute time is blown out of the water. Our ECPR population has an average of 60 minutes of CPR time, so more than double. So the time for that neurologic injury is extensive." — Dr. Andrea Elliott[18:43] "You can actually get into trouble if with some under-resuscitation and some patients, if you get them too cold too quickly, and so you'll have to give extra volume back."— Dr. Andrea Elliott[22:37] "The most important thing is to make sure that you avoid fevers in our ECPR patients. We also use cooling towers, so we basically cool the fluid or the blood that is in the tubing outside of the patient so that it goes through a cooling bath."— Dr. Andrea ElliottResources and LinksBecome a member of the Community: https://www.soccc.org/subscribeDr. Andrea Elliotthttps://med.umn.edu/bio/andrea-elliotthttps://www.linkedin.com/in/andrea-elliott-5575b4267/Dr. Balim Senmanhttps://www.linkedin.com/in/balim-senman-7561436b/https://x.com/BalimSenmanMDhttps://www.soccc.org/Supported By:This episode is made possible by unrestricted support from Zoll LifeVest — thanks for keeping high-impact education free for our community.DisclaimerThis podcast is not medical advice, just candid, practical discussions about what your hosts do every day in the CICU. Always consult your supervising team and current guidelines before applying any interventions.
    続きを読む 一部表示
    22 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません